Quantum Biopharma (NASDAQ:QNTM) Posts Quarterly Earnings Results, Misses Expectations By $0.49 EPS

Quantum Biopharma (NASDAQ:QNTM) released its quarterly earnings data on Thursday. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.49), Zacks reports.

Quantum Biopharma Stock Performance

Shares of QNTM stock traded up $0.02 on Friday, hitting $3.85. The company had a trading volume of 60,009 shares, compared to its average volume of 228,635. Quantum Biopharma has a twelve month low of $2.07 and a twelve month high of $38.25. The firm has a market cap of $14.69 million, a P/E ratio of -0.35 and a beta of 0.32. The stock’s 50-day moving average is $4.01 and its two-hundred day moving average is $8.91.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Quantum Biopharma in a research report on Monday, December 29th. Wall Street Zen downgraded shares of Quantum Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, January 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Trading of Quantum Biopharma

A hedge fund recently bought a new stake in Quantum Biopharma stock. Virtu Financial LLC purchased a new stake in shares of Quantum Biopharma Ltd. (NASDAQ:QNTM) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 10,406 shares of the company’s stock, valued at approximately $76,000. Virtu Financial LLC owned about 0.27% of Quantum Biopharma at the end of the most recent quarter. Institutional investors and hedge funds own 1.24% of the company’s stock.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.